1-Hexan-3-yl-4-methylsulfonylbenzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Hexan-3-yl-4-methylsulfonylbenzene
• 英文别名: 1-hexan-3-yl-4-methylsulfonylbenzene
• 化学式: C₁₃H₂₀O₂S
• 分子量: 240.36
• InChiKey: OMYMADLOWVYTDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20180193352A1

  公开（公告）日：2018-07-12

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: These compounds are useful for treating Respiratory Syncytial Virus (RSV) infection. The present invention further relates to pharmaceutical compositions comprising these compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the invention.

  本发明公开了化合物I的结构，以及其药用可接受的盐、酯或前药：这些化合物对治疗呼吸道合胞病毒（RSV）感染有用。本发明还涉及包含这些化合物的药物组合物，用于给患有RSV感染的受试者使用。该发明还涉及通过向受试者给予包含本发明化合物的药物组合物来治疗受试者的RSV感染的方法。
• Heteroaryldiazepine derivatives as RSV inhibitors
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US10398706B2

  公开（公告）日：2019-09-03

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: These compounds are useful for treating Respiratory Syncytial Virus (RSV) infection. The present invention further relates to pharmaceutical compositions comprising these compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the invention.

  本发明公开了式（I）化合物及其药学上可接受的盐、酯或原药： 这些化合物可用于治疗呼吸道合胞病毒（RSV）感染。本发明进一步涉及包含这些化合物的药物组合物，用于给患有 RSV 感染的受试者用药。本发明还涉及通过向受试者施用包含本发明化合物的药物组合物来治疗受试者 RSV 感染的方法。
• SHP2 phosphatase inhibitors and methods of use thereof
  申请人：Relay Therapeutics, Inc.

  公开号：US11529347B2

  公开（公告）日：2022-12-20

  The present invention relates to novel compounds having the general formula: and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for suppressing tumor cell growth, ameliorating the pathogenesis of systemic lupus erythematosus, and the treatment of various other disorders, including Noonan syndrome, diabetes, neutropenia, neuroblastoma, melanoma, juvenile leukemia, juvenile myelomonocytic leukemia, chronic myelomonocytic leukemia, acute myeloid leukemia, and other cancers associated with SHP2 deregulation with the compounds and compositions of the invention, alone or in combination with other treatments. Other cancers associated with SHP2 deregulation include HER2-positive breast cancer, triple-negative breast cancer, ductal carcinoma of the breast, invasive ductal carcinoma of the breast, non-small cell lung cancer, esophageal cancer, gastric cancer, squamous-cell carcinoma of the head and neck (SCCHN), and colon cancer.

  本发明涉及具有通式的新型化合物： 及其药物组合物，以及用本发明化合物和组合物抑制SHP2磷酸酶活性的方法。本发明进一步涉及但不限于抑制肿瘤细胞生长、改善系统性红斑狼疮的发病机理以及治疗其他各种疾病的方法，包括努南综合征、糖尿病、中性粒细胞减少症、神经母细胞瘤、黑素瘤、幼年白血病、肌瘤、白血病、白血病综合征、白血病、白血病综合征、白血病综合征、白血病综合征、白血病综合征、白血病综合征、白血病综合征、白血病综合征、白血病综合征、黑素瘤、幼年白血病、幼年髓单核细胞白血病、慢性髓单核细胞白血病、急性髓性白血病以及其他与 SHP2 失调相关的癌症，可单独使用或与其他疗法联合使用本发明的化合物和组合物。与SHP2失调相关的其他癌症包括HER2阳性乳腺癌、三阴性乳腺癌、乳腺导管癌、浸润性乳腺导管癌、非小细胞肺癌、食管癌、胃癌、头颈部鳞状细胞癌（SCCHN）和结肠癌。
• SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
  申请人：Relay Therapeutics, Inc.

  公开号：US20190307745A1

  公开（公告）日：2019-10-10

  The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for suppressing tumor cell growth, ameliorating the pathogenesis of systemic lupus erythematosus, and the treatment of various other disorders, including Noonan syndrome, diabetes, neutropenia, neuroblastoma, melanoma, juvenile leukemia, juvenile myelomonocytic leukemia, chronic myelomonocytic leukemia, acute myeloid leukemia, and other cancers associated with SHP2 deregulation with the compounds and compositions of the invention, alone or in combination with other treatments. Other cancers associated with SHP2 deregulation include HER2-positive breast cancer, triple-negative breast cancer, ductal carcinoma of the breast, invasive ductal carcinoma of the breast, non-small cell lung cancer, esophageal cancer, gastric cancer, squamous-cell carcinoma of the head and neck (SCCHN), and colon cancer.
• FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF
  申请人：JAZZ PHARMACEUTICALS IRELAND LIMITED

  公开号：US20220033398A1

  公开（公告）日：2022-02-03

  The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method of using the compound of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.